title: Nomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
abstract: OBJECTIVE
  The aim of this study was to combine clinical pathologic variables that are associated with pathologic completer response (pCR) and relapse-free survival (RFS) after neoadjuvant chemotherapy into prediction nomograms.
  
  
  METHODS
  A total of 370 stage II or III breast cancer patients who received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We developed the nomograms using logistic regression model for pCR and Cox proportional hazard regression model for RFS.
  
  
  RESULTS
  The nomogram for pCR based on initial tumor size, estrogen receptor (ER), human epidermal growth factor receptor 2, and Ki67 had good discrimination performance (AUROC = 0.830). Multivariate Cox model identified age less than 35, initial clinical stage, pathologic stage, ER, Ki67 as prognostic factors, and the nomogram for RFS was developed based on these covariates. The concordance index for the second nomogram was 0.781, and calibration was also good.
  
  
  CONCLUSIONS
  We developed nomograms based on clinical and pathologic characteristics to predict the probability of pCR and RFS for patients receiving neoadjuvant docetaxel/doxorubicin chemotherapy.
authors: Department of Internal Medicine, Seoul National University College of Medicine, 28 Yongon-Dong, Chongno-Gu, Seoul, 110-744, Korea.
authors: Bhumsuk
authors: B
authors: Keam
authors: Seock-Ah
authors: SA
authors: Im
authors: Sohee
authors: S
authors: Park
authors: Byung-Ho
authors: BH
authors: Nam
authors: Sae-Won
authors: SW
authors: Han
authors: Do-Youn
authors: DY
authors: Oh
authors: Jee Hyun
authors: JH
authors: Kim
authors: Se-Hoon
authors: SH
authors: Lee
authors: Wonshik
authors: W
authors: Han
authors: Dong-Wan
authors: DW
authors: Kim
authors: Tae-You
authors: TY
authors: Kim
authors: In Ae
authors: IA
authors: Park
authors: Dong-Young
authors: DY
authors: Noh
authors: Dae Seog
authors: DS
authors: Heo
authors: Yung-Jue
authors: YJ
authors: Bang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D002277:Carcinoma / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D049451:Nomograms; D011379:Prognosis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin